Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement

Performance Highlights:
During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable... | March 28, 2023

Related Keywords

United States ,India ,China ,Macao ,Macau General ,Macau ,Australia ,Hong Kong ,Taiwan ,Shanghai ,Chinese ,Fosun Pharma Artesun ,Han Li Kang Rituximab ,Getz Pharma ,Parsabiv Etelcalcetide ,Han Si Zhuang Serplulimab ,Han Li Kang ,Fosun Pharma ,Tridem Pharma ,Wu Yifang ,Han Si Zhuang ,National Medical Insurance Drug Catalogue ,European Commission ,National Reimbursement Drug List ,Amgen ,Rating Expert Committee ,Cipla ,Sinopharm Co Ltd ,Innovation For Good Health ,Performance Highlights ,Han Qu You ,Chinese Mainland ,Shanghai Fosun Pharmaceutical ,Stock Code ,Reporting Period ,Increased Rd Investment ,Remarkable Results ,Serplulimab Injection ,Microsatellite Instability High ,Non Small Cell Lung Cancer ,Extensive Stage Small Cell Lung Cancer ,Small Cell Lung Cancer ,Orphan Drug Designation ,Rheumatoid Arthritis ,Reimbursement Drug ,Emergency Use Authorization ,Azvudine Tablets ,Genuine Biotech ,National Medical Products Administration ,Hydrochloride Tablets ,Bei Wen ,Fosun Kite ,Continuously Improvement ,Global Operation ,Apremilast Tablets ,Shanghai Henlius ,Gland Pharma ,Active Practice ,Good Health ,Innovation Transformation ,Integrated Operation ,Steady Growth ,Looking Statement ,Shanghai Fosun Pharmaceutical Group Co ,Td Stock Exchange ,News ,Information ,Press Release ,Performance ,The ,Reporting ,Revenue ,Gas ,Bomb ,Ith ,Growth ,F ,Pet ,Profit ,After ,Deducting ,Xtraordinary ,Rain ,Dr ,Oss 2196 Cne100001m79 ,